Business Wire

Business Figures for the First Half of 2018: Sartorius Records Double-Digit Sales Growth

Del

Sartorius, a leading international partner of the biopharmaceutical industry and the research sector, continued on the growth track, with significant increases in sales revenue and earnings. “The first half of 2018 was very successful overall for Sartorius,” commented CEO Joachim Kreuzburg on the results after six months. “We grew dynamically in our two divisions and in all regions and, despite currency headwinds, further increased our profit margin. Due to the dynamics that were slightly above our expectations in Bioprocess Solutions, we have raised our sales forecast for this division and thus for the entire Group.”

Business development of the Sartorius Group

In the first half of 2018, Sartorius increased its sales revenue by 11.9% (reported: +8.0%) in constant currencies to 758.4 million euros. Acquisitions contributed around 2 percentage points to this positive business performance. Order intake rose somewhat more strongly than sales revenue and was up 12.7% (reported: +8.9%).

Regionally, the Americas recorded the highest dynamics. Sales in this region were up 16.6% to 249.6 million euros, relative to a moderate revenue base in the previous year. In Asia|Pacific, Sartorius also grew by double digits, with sales up 12.2% to 184.4 million euros, while the company achieved higher revenue in the EMEA2) region, recording 324.4 million euros, 8.4% up from the comparable period a year ago (regional growth rates in constant currencies).

Earnings also increased robustly: Underlying EBITDA rose 9.6% to 189.5 million euros, despite negative currency effects that occurred especially in the first quarter. The Group’s underlying EBITDA margin improved to 25.0% compared with 24.6% a year ago. Relevant net profit3) for the Group grew even more significantly, by 14.1% from 69.9 million euros to 79.8 million euros. This corresponds to earnings per ordinary share of 1.16 euros (H1 2017: 1.02 euros) and per preference share of 1.17 euros (H1 2017: 1.03 euros).

The Group's key financial indicators continued to remain at robust levels. At the end of the reporting period, the company's equity ratio was 34.9% and its ratio of net debt to underlying EBITDA1) stood at 2.6 (Dec. 31, 2017: 35.1% and 2.5, respectively). The first-half capex ratio was 13.2%, approximately at the previous year’s level and thus within the planned range. Investment activities continued to focus on expansion of the plant for manufacturing single-use bags and filters in Puerto Rico, as well as on the combination and expansion of Group headquarters and production capacity levels in Göttingen, Germany.

As of the reporting date on June 30, 2018, Sartorius employed 7,738 people worldwide, 237 more than as of December 31, 2017 (approx. +3%).

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacturing of biopharmaceuticals, recorded sales growth of 11.9% in constant currencies to 550.3 million euros (reported: +7.9%) after dynamic business performance in the second half. Consolidation of Umetrics acquired in the previous year contributed close to one percentage point of non-organic growth to sales expansion. Order intake also rose slightly more strongly than expected, up 12.6% in constant currencies (reported: +8.7%).

Underlying EBITDA for the division increased by 10.0% to 153.9 million euros due to economies of scale and despite negative currency effects. The division's corresponding margin was 28.0% relative to 27.4% in the prior-year period.

The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and for life science research, grew by double digits, with sales up 12.0% in constant currencies (reported: +8.1%) to 208.1 million euros. While the division’s organic growth was around 7%, the prior-year acquisition of Essen BioScience, a specialist in cell analysis, contributed non-organic growth of around 5 percentage points. First-half order intake for the division was up 13.1% in constant currencies (reported: +9.2%).

Recording a gain of 7.8%, Lab Products & Services increased its underlying EBITDA from 33.0 million euros to 35.5 million euros. Within the context of the less favorable currency environment its margin remained at the prior-year figure of 17.1%.

Forecast for the full year of 2018 raised

In view of strong business performance in the first half of 2018, management has raised its sales forecast for the Bioprocess Solutions Division and thus for the entire Group. Consolidated sales revenue is projected to grow by about 12% to 15% (previous guidance: 9% to 12%). The Group’s underlying EBITDA margin is still expected to increase by 0.5 percentage points compared with the year-earlier figure of 25.1%.

Given the dynamic growth of sales revenue and order intake in the first half for the Bioprocess Solutions Division, management now projects that division sales will increase by about 12% to 15% (previous guidance about 8% to 11%). This figure includes a non-organic growth contribution of slightly less than 0.5 percentage points. The division's underlying EBITDA margin is forecasted to gain about half a percentage point over the prior-year figure of 28.0%.

For the Lab Products & Services Division, guidance remains unchanged. Sartorius expects division sales to grow by about 12% to 15%, which includes more than 2.5 percentage points of non-organic growth expected to be contributed by Essen BioScience that was consolidated as of the end of March in 2017. The division’s underlying EBITDA margin is projected to rise by around one percentage point (previous year: 18.0%).

All forecasts are based on constant currencies. Due to the latest foreign exchange developments, our results reported in actual currencies may differ. We will explain any particular effects that occur during 2018.

1) Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization; adjusted for extraordinary items) as the key profitability indicator
2) EMEA = Europe | Middle East | Africa
3) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Current image files

Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications
https://www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg

Sartorius products used in pharmaceutical research
www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg

Conference call

Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, and Rainer Lehmann, CFO of Sartorius, will discuss the company's business results with analysts and investors on Tuesday, July 24, 2018, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link:
http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=2924053&linkSecurityString=122e29ee9

Alternatively, you can dial into the teleconference, without registering, at:
+49 (0) 69 566 03 6000

The company presentation will be available on July 24, 2018, starting at 3:15 p.m. CET, for viewing on our website at:
http://www.sartorius.com/com/group/investor-relations/sartorius-ag/

Upcoming financial date:

October 23, 2018 Publication of nine-month figures (January to September 2018)

A profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.4 billion euros in 2017. More than 7,500 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.

Key Figures for the First Half of 2018

             
Sartorius Group Bioprocess Solutions Lab Products & Services
In millions of € (unless otherwise specified)      

H1
2018

    H1
20175)
   

Δ∆ in %
Reported

   

Δ∆ in %
cc1)

    H1
2018
    H1
20175)
   

Δ∆ in %
Reported

     

Δ∆ in %
cc1)

    H1
2018
    H1
20175)
   

Δ∆ in %
Reported

   

Δ∆ in %
cc1)

Sales Revenue and Order Intake
Sales revenue       758.4     702.5     8.0     11,9     550.3     510.1     7.9       11,9     208.1     192.4     8.1     12.0

- EMEA2)

      324.4     301.8     7.5     8,4     229.5     208.5     10.0       10,7     94.9     93.3     1.8     3.3
- Americas2)       249.6     228.5     9.3     16,6     195.8     181.3     8.0       15,4     53.9     47.2     14.1     20.9
- Asia | Pacific2)       184.4     172.2     7.1     12,2     125.1     120.3     4.0       8,9     59.3     51.9     14.2     19.9
Order intake       807.6     741.9     8.9     12,7     594.6     546.9     8.7       12,6     213.0     195.0     9.2     13.1
Earnings
EBITDA3)       189.5     172.9     9.6           153.9     140.0     10.0             35.5     33.0     7.8      
EBITDA margin3) in %       25.0     24.6                 28.0     27.4                   17.1     17.1            
Net profit for the period4)       79.8     69.9     14.1                                                        
Financial Data per Share

Earnings per ordinary share4) in €

      1.16     1.02     14.1                                                        

Earnings per preference share4) in €

      1.17     1.03     14.0                                                        
 

1) In constant currencies

2) Acc. to the customer’s location

3) Adjusted for extraordinary items

4) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

5) The previous year's figures have been restated due to the finalization of the purchase price allocations for the acquisitions of 2017

 

Contact information

Sartorius AG
Petra Kirchhoff, +49 (0)551.308.1686
Head of Corporate Communications
petra.kirchhoff@sartorius.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

SIAE MICROELETTRONICA Outperforms Telefónica 10Gbps E-band Tests to Power 5G Backhauling10.12.2018 08:00Pressemelding

Telefónica a global leader mobile operator and SIAE MICROELETTRONICA a leader in wireless transport technology have put to the test the high capacity 10Gbps wireless links to enhance the backhauling network for the future advent of 5G. The millimetre-wave point-to-point radio operating at 80GHz E band carrier, offers the lowest transport latency and the highest wireless capacity of 10Gbps over a single channel, satisfying the strict 5G requirements. Telefónica successfully field tested SIAE MICROELETTRONICA millimetre-wave radio solution in two use cases: 10Gbps point-to-point links addressing urban applications and the multicarrier link aggregation addressing the sub-urban applications, pushing high capacity connectivity to longer distances. “SIAE MICROELETTRONICA and Telefónica have cooperated over multiple projects all aiming to satisfy the 5G backhaul requirements. From microwave SDN applications to the introduction of state of the art millimetre-wave radio, once again crossing tog

Fishawack Acquires Creative Consultancy Blue Latitude Health10.12.2018 07:00Pressemelding

The Fishawack Group of Companies, one of the world’s largest independent medical communications and medical marketing organizations, has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181209005023/en/ Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row from left to right). (Photo: Business Wire) “In 2016, we set out our vision to form a major new force in the global creative agency space that would make us as strong in the creative arena as we already are in medical communications,” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “With three acquisitions in this space in the last 16 months, I think we’ve firmly announced our intention t

Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer10.12.2018 06:00Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. O’Day is currently the CEO of Roche Pharmaceuticals. He has held the position since 2012, and prior to that led Roche Diagnostics. His career spans three decades of diverse leadership roles across North America, Asia Pacific and Europe. The Board has also appointed Gregg Alton as interim Chief Executive Officer for the period of January 1, 2019 until Mr. O’Day’s start date of March 1, 2019. Mr. Alton has held a number of executive positions at Gilead over the past 20 years, with experience in legal, medical affairs, policy and commercial. He previously served as general counsel and in August of this year, was appointed Chief Patient Officer. “Following a comprehensive search, the Board became convinced that Dan is the right leader to bring Gilead into the future,” said John C. Martin, PhD, Chairman, Gilea

Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity8.12.2018 14:10Pressemelding

Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing HERCEPTIN® 1 (trastuzumab), to reference trastuzumab (TRZ) by antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is a key mechanism of action for trastuzumab. The study results are being presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. For the study, patients with HER2 positive early or locally advanced breast cancer were randomly assigned to receive SB3 or TRZ concurrently with chemotherapy. Patients then underwent surgery followed by treatment with SB3 or TRZ. Following completion of such therapy, 367 patients participated in a long-term follow-up study, 186 of whom were treated with SB3 and 181 of whom were treated with TRZ. Within the group of 181 patients who received TRZ, 126 patients who were exposed to at least

Harvest Health & Recreation, Inc. to hold Conference Call to Discuss Q3 2018 Results and Performance Outlook7.12.2018 19:00Pressemelding

Harvest Health & Recreation, Inc. (HARV: CSE) will hold its Third Quarter 2018 earnings conference call on: Tuesday, December 11, 2018 8:30 AM (Eastern Time) Participating on the call to review Harvest Health & Recreation’s Third Quarter 2018 financial and operating results will be Jason Vedadi, Executive Chairman, Steve White, Chief Executive Officer, and Steve Gutterman, President. Third quarter results are available at www.harvestinc.com/news. To participate in the conference call, please dial: US toll free +1-866-777-2509 Canada toll free +1-866-605-3852 UK toll free +44-080-823-89064 International dial in +1-412-317-5413 Registration is required; please dial in at least ten minutes prior to the scheduled start time. Webcast: https://services.choruscall.com/links/harv181211.html The conference call will be available for replay for 3 months at: https://services.choruscall.com/links/harv181211.html. About Harvest Health & Recreation, Inc. Harvest Health & Recreation, Inc. is one of t

David Hall Wows Industry with New Technology Solution for Space Exploration7.12.2018 14:01Pressemelding

David Hall is one of history’s rare technological visionaries with the imagination and technical wherewithal to recognize a problem, conceive a solution, and then build something that works. On December 6 at the U.S. Chamber of Commerce’s event, LAUNCH: Industry Taking Off, David Hall presented his world-changing solution to a longstanding problem: how to carry materials and people into space safely, reliably, and efficiently. The audience of industry, military, and policy representatives heard from Hall as well as keynote remarks from Secretary of the Air Force, Heather Wilson; NASA Administrator, Jim Bridenstine; Under Secretary of Defense for Research and Engineering, Michael Griffin; NOAA Deputy Administrator, Dr. Neil Jacobs; and Commerce Secretary, Wilbur Ross. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181207005226/en/ Velodyne Lidar, Inc. Founder and CEO David Hall (Photo: Business Wire) Hall’s proposal involves